VC 004
Alternative Names: VC-004Latest Information Update: 18 Dec 2024
Price :
$50 *
At a glance
- Originator Jiangsu Vcare Pharmatech
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 31 Oct 2024 Jiangsu Vcare Pharmatech completes a phase I pharmacokinetic trial (In volunteers) in China (PO) (NCT06619951)
- 30 Oct 2024 Jiangsu vcare pharmaceutical technology plans a phase III trial for Solid tumours (Late-stage disease, Metastatic disease) in China (NCT06658353)
- 01 Oct 2024 Jiangsu Vcare Pharmatech plans a phase I pharmacokinetic trial (In volunteers) in China (PO), in October 2024 (NCT06619951)